Biopharma sets new record: $6.6B civil/criminal settlements in 2012, so far
This article was originally published in Scrip
2012 already is a banner year for drug makers, although the new record set is likely one the industry would prefer to ignore – paying out big bucks to states and the US federal government to settle various charges, such as illegal off-label marketing or overcharging Medicare and Medicaid or other taxpayer-funded health care programs, with firms doling out $6.6 billion as of mid-July, the consumer watchdog Public Citizen reported.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.